IDNA - Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point
- Two ongoing studies for use of paltusotine for treatment of patients with Acromegaly are PATHFNDR-1 and PATHFNDR-2; Results from both studies expected 2023.
- Paltusotine is also being explored for the treatment of patients with neuroendocrine tumors in a phase 2 study.
- Phase 1 proof of concept was established with CRN04777 for treatment of patients with congenital hyperinsulinism; phase 2 study expected to start 2nd half of 2022.
- Crinetics has around $444.7 million in cash including the most recent offering done in April of 2022, it believes that all this cash should be enough to fund its operations into the 2nd half of 2024.
For further details see:
Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point